Based on these facts, a retrospective study of the AVAglio trial compared the effects of BEV treatment on proneural GBM and three other subtypes of GBM (including only wild‐type IDH1).16, 23 The results showed beneficial effects on PFS in the proneural (9.9 vs 5.7 months; hazard ratio [HR]: 0.57; 95% CI: 0.37‐0.89; adjusted log‐rank P = 0.036; n = 103) and mesenchymal (10.1 vs 5.8 months; HR: 0.57; 95% CI: 0.40‐0.82; adjusted log‐rank P = 0.0076) subtypes. The gene discussed is IDH1; the disease is glioblastoma.